Zoetis confirms restock of canine osteoarthritis drug Trocoxil

Animal Health Supplier News

Zoetis has confirmed that Trocoxil, its once-monthly treatment for canine osteoarthritis, has been restocked following a recent supply shortage.

The chewable tablets are used for the treatment of pain and inflammation associated with degenerative joint disease in dogs aged 12 months or over. Zoetis was recently forced to stop production of the medicine to prioritise other therapies, such as Apoquel and Palladia.

“Zoetis has brought its canine osteoarthritis therapy Trocoxil back in stock following a recent supply shortage.“

This decision was taken on animal welfare grounds, but the company has since been able to restore full stock levels of all of these products, allowing the manufacture of Trocoxil to resume. Sales of the product will recommence this month.

Ned Flaxman, business unit director for companion animal, equine and innovation at Zoetis, said: "I would like to thank our veterinary clients for their patience and reassure them that we brought the product back to market as quickly as we could, and do not anticipate any further stock issues."

Trocoxil belongs to a class of therapies known as nonsteroidal anti-inflammatory drugs, and has been shown to help reduce arthritis pain in dogs.

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Animal Health
Return to news

Tags